Regenacy Pharmaceuticals Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$9.3M
- Investors
-
7
Regenacy Pharmaceuticals General Information
Description
Developer of therapeutic drugs based on the novel, disease-modifying approach intended for the treatment of peripheral neuropathy. The company's drugs utilize regeneration of normal protein function using oral, isoform-selective histone deacetylase enzyme inhibitors to develop selective HDAC6 inhibitor ricolinostat, enabling physicians to treat sickle cell disease and beta-thalassemia.
Contact Information
Website
www.regenacy.comCorporate Office
- 303 Wyman Street
- Suite 300
- Waltham, MA 02451
- United States
Corporate Office
- 303 Wyman Street
- Suite 300
- Waltham, MA 02451
- United States
Regenacy Pharmaceuticals Timeline
Regenacy Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series B) | 24-Aug-2022 | $9.3M | Completed | Clinical Trials - Phase 2 | ||
| 3. Later Stage VC (Series B) | 09-Feb-2022 | Completed | Clinical Trials - Phase 2 | |||
| 2. Early Stage VC (Series A) | 19-Mar-2020 | $30M | $30M | Completed | Clinical Trials - Phase 2 | |
| 1. Angel (individual) | Completed | Startup |
Regenacy Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
Regenacy Pharmaceuticals Comparisons
Industry
Financing
Details
Regenacy Pharmaceuticals Competitors (20)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Corvus Pharmaceuticals | Formerly VC-backed | Burlingame, CA | ||||
| Virometix | Venture Capital-Backed | Schlieren, Switzerland | ||||
| viDA Therapeutics | Venture Capital-Backed | Vancouver, Canada | ||||
| Cortalix | Venture Capital-Backed | Groningen, Netherlands |
Regenacy Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Regenacy Pharmaceuticals Patents
Regenacy Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210332036-A1 | Pyrimidine and pyrazine hdac1,2 inhibitors | Inactive | 10-Oct-2018 | ||
| CA-3113819-A1 | Pyrimidine and pyrazine hdac1,2 inhibitors | Pending | 10-Oct-2018 | ||
| EP-3863631-A1 | Pyrimidine and pyrazine hdac1,2 inhibitors | Inactive | 10-Oct-2018 | ||
| EP-3863631-A4 | Pyrimidine and pyrazine hdac1,2 inhibitors | Inactive | 10-Oct-2018 | ||
| US-20220033388-A1 | Hdac1,2 inhibitors | Active | 25-Sep-2018 | C07D409/12 |
Regenacy Pharmaceuticals Executive Team (7)
| Name | Title | Board Seat |
|---|---|---|
| Simon Jones Ph.D | Chief Executive Officer & President | |
| John Rocha | Chief Financial Officer | |
| David Michelson MD | Chief Medical Officer | |
| William Chin MD | Member of Scientific Advisory Board |
Regenacy Pharmaceuticals Board Members (14)
| Name | Representing | Role | Since |
|---|---|---|---|
| Daguang Wang Ph.D | Self | Board Member | |
| Michael Huang | Taiwania Capital | Vice Chairman | |
| S. Yan Ph.D | 3E Bioventures (China) | Board Member | |
| Shixiang Yan | Self | Board Member | |
| Todd Kaloudis | Cobro Ventures | Board Member |
Regenacy Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Regenacy Pharmaceuticals Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 3E Bioventures (China) | Venture Capital | Minority | ||
| Cobro Ventures | Venture Capital | Minority | ||
| Rivas Capital | Venture Capital | Minority | ||
| Taiwania Capital | Venture Capital | Minority | ||
| TA YA VENTURE HOLDINGS LIMITED | Venture Capital | Minority |
Regenacy Pharmaceuticals Investments (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| BC Regenacy | 14-Jul-2020 | Drug Discovery |
Regenacy Pharmaceuticals FAQs
-
When was Regenacy Pharmaceuticals founded?
Regenacy Pharmaceuticals was founded in 2016.
-
Who is the founder of Regenacy Pharmaceuticals?
Matthew Jarpe Ph.D, Marc Cohen, and Walter Ogier are the founders of Regenacy Pharmaceuticals.
-
Who is the CEO of Regenacy Pharmaceuticals?
Simon Jones Ph.D is the CEO of Regenacy Pharmaceuticals.
-
Where is Regenacy Pharmaceuticals headquartered?
Regenacy Pharmaceuticals is headquartered in Waltham, MA.
-
What is the size of Regenacy Pharmaceuticals?
Regenacy Pharmaceuticals has 9 total employees.
-
What industry is Regenacy Pharmaceuticals in?
Regenacy Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Regenacy Pharmaceuticals a private or public company?
Regenacy Pharmaceuticals is a Private company.
-
What is Regenacy Pharmaceuticals’s current revenue?
The current revenue for Regenacy Pharmaceuticals is .
-
How much funding has Regenacy Pharmaceuticals raised over time?
Regenacy Pharmaceuticals has raised $47.1M.
-
Who are Regenacy Pharmaceuticals’s investors?
3E Bioventures (China), Cobro Ventures, Rivas Capital, Taiwania Capital, and TA YA VENTURE HOLDINGS LIMITED are 5 of 7 investors who have invested in Regenacy Pharmaceuticals.
-
Who are Regenacy Pharmaceuticals’s competitors?
NexImmune, Corvus Pharmaceuticals, Virometix, viDA Therapeutics, and Cortalix are some of the 20 competitors of Regenacy Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
